Research
A two-part nanozyme targets the inflammatory loop linked to colon cancer
Nanowerk ·
The Brief
- Researchers combined an antioxidant nanomaterial with a chemokine-binding cell membrane to form a two-part nanozyme.
- The nanozyme reduced tumor development in mouse models of colitis-associated cancer, according to the Nanowerk report.
- The work targets the inflammatory loop linked to colon cancer; the source reports results in mice only.
Why it matters
It shows a proposed strategy that disrupts inflammation driving colitis-associated colon cancer, a possible direction for future therapies, though results so far come from animal models.
Who’s affected
- researchers in nanomedicine and colorectal cancer
- clinicians and patients with inflammatory bowel disease who face elevated colon cancer risk
- #nanozyme
- #colon cancer
- #colitis
- #inflammation
- #nanomedicine
- #chemokines
By combining an antioxidant nanomaterial with a chemokine-binding cell membrane, researchers have reduced tumor development in mouse models of colitis-associated cancer.
Timeline
Nanowerk reports the two-part nanozyme reducing tumor development in mouse models of colitis-associated cancer
Nanowerk Nanotechnology and Emerging Technologies News
A two-part nanozyme targets the inflammatory loop linked to colon cancer